Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06129591 · ClinicalTrials.gov registry record · Phase 1
Topical CBD Scar Healing Study
A Phase 1 study, sponsored by University of Oklahoma.
- Not yet
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT06129591: Clinical Trial Phase 1 study, sponsored by University of Oklahoma.
NCT06129591 is a Phase 1 study that has not yet begun recruiting, run by University of Oklahoma. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06129591, a Phase 1 study, has not yet begun recruiting, sponsored by University of Oklahoma.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects (good and bad) that cannabidiol (CBD) has on scar healing and appearance in patients who have undergone paramedian forehead flap reconstruction.
Primary Outcome
Proportion of patients who have a positive effect using CBD oil in combination with the silicone patch. This will be assessed using the Scar Cosmesis Assessment and Rating (SCAR) scale to determine the impact of CBD oil and silicon patch combo. This photographic evaluation of scare will be done over a period of around 7 months to evaluate the scar outcomes, using the scoring system with minimum score of 0 (being best possible outcome) and maximum score of 13 (worst possible scar outcome).
Interventions
- DRUG Vantage Hemp CBD Isolate + Silicone patch
- DRUG Silicone patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2026-05 |
| Est. Completion | 2028-07 |
| Phase | Phase 1 |
What is known before NCT06129591 opens enrollment
NCT06129591 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 2 interventions - of which Vantage Hemp CBD Isolate + Silicone patch is the first listed.
NCT06129591 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06129591 about?
NCT06129591 is a clinical study titled "Topical CBD Scar Healing Study". The purpose of this study is to find out what effects (good and bad) that cannabidiol (CBD) has on scar healing and appearance in patients who have undergone paramedian forehead flap reconstruction.
What is the current status of trial NCT06129591?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2026-05. Estimated completion is 2028-07.
What interventions are being tested in trial NCT06129591?
The interventions under investigation include: Vantage Hemp CBD Isolate + Silicone patch (DRUG), Silicone patch (DRUG).
Who is sponsoring clinical trial NCT06129591?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06129591's enrollment target sits among peer trials
22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia